4'-Hydroxy-3'-methylacetophenone, a phenolic volatile compound, is isolated from Hawaiian green coffee beans (Coffea Arabica L.). 4'-Hydroxy-3'-methylacetophenone has potent antioxidant activities. 4'-Hydroxy-3'-methylacetophenone also can be used to synthesize heterocyclic compounds which have antimycobacterial activity.

Dibutyltin dilaurate is used in prevention of parasitic dieases in cattle and sheep.

Lipid 15 is the lead ionizable cationic lipid (ICL) for CD8-targeted mRNA-LNPs. As the core LNP component, Lipid 15 yields ~100 nm uniform particles with near-neutral surface charge at physiological pH, while becoming strongly cationic in acidic endosomes—reducing hepatic off-target uptake and enabling efficient endosomal escape to release mRNA. Versus other ICL candidates, Lipid 15 achieves far higher mRNA transfection efficiency in primary human CD8⁺ T cells, supports robust transient CAR expression, and triggers minimal cytokine release in immunogenicity assays. It retains structural and functional stability after freeze storage. When formulated into anti-CD8 VHH-conjugated LNPs carrying CD22 CAR mRNA, Lipid 15 drives specific in vivo reprogramming of circulating CD8⁺ T cells into functional CAR-T cells, delivering potent tumor suppression in humanized hematological malignancy models without overt toxicity.

KT-474 is a highly active and selective, orally bioavailable IRAK4 degrader being developed for the treatment of toll-like receptor (TLR)/interleukin-1 receptor (IL-1R)-driven immune-inflammatory diseases.

CFT8634 is an oral activity degrader targeting BRD9 extracted from patent WO2021178920A1 compound 174. CFT8634 can be used for the research of synovial sarcoma and SMARCB1-deleted solid tumors.

NX-5948,be also known as BTK-IN-24,is an oral BTK degrader.

XNW34017 is a PROTAC targeting Aurora A. It binds both Aurora A and the E3 ligase CRBN, leading to ubiquitination of Aurora A by CRBN, followed by specific degradation via the ubiquitin-proteasome system (UPS). This results in cell cycle arrest and apoptosis, thereby killing tumor cells.

ZZ7-23-022 (ZZ7) is a selective BRD9 molecule glue degrader. ZZ7-23-022 effectively degrades BRD9 in synovial sarcoma cells, but does not affect cardiomyocytes. ZZ7-23-022 can be used for the research of cancer.

AMX-883 a selective and orally active BRD9 molecular glue degrader that drives differentiation in acute myeloid leukaemia. AMX-883 shows selectivity over all other bromodomain containing proteins and proteome wide. AMX-883 does not employ the commonly used E3 ligases (cereblon, VHL) but instead drives degradation via DCAF16 as a targeted glue. AMX-883 can be used for the study of acute myeloid leukaemia (AML).

MRT-55811 is a first-in-class, highly selective CCNE1-targeting molecular glue degrader that achieves selective targeting of a previously undruggable target.

TNG961 functions as an orally available, selective molecular glue degrader that targets HBS1L. It is intended for the treatment of tumors characterized by FOCAD deficiency.

MRT-8102 is a molecular glue degrader that targets the NEK7 protein for the treatment of NLRP3 inflammasome-mediated inflammatory diseases.

NST-628 is a brain-penetrant molecular glue targeting the MAPK pathway, effectively inhibiting RAF phosphorylation and MEK activation. By binding to RAF, it disrupts the formation of BRAF-CRAF and BRAF-ARAF heterodimers, thereby blocking the RAS-MAPK signaling cascade. NST-628 exhibits potent anti-tumor activity in RAS- and RAF-driven cancers, demonstrating significant efficacy in mutant KRAS, NRAS, BRAF class II/III, and NF1-mutant tumor models.

NEO-811 is a molecular glue degrader specifically directed against ARNT (also known as HIF-1β). It demonstrates potent antitumor activity as a monotherapy in clear cell renal cell carcinoma (ccRCC).

TRI-611 is a highly potent and selective molecular glue degrader targeting ALK, with the ability to cross the blood-brain barrier. It is designed for the treatment of non-small cell lung cancer that tests positive for ALK fusion proteins.

TGFβRI-IN-2 (compound 18) is a potent, selective and orally active (Activin-Like Kinase 5) ALK 5 inhibitor with pIC50 and pEC50 values of 7.6 and 6.63, respectively. TGFβRI-IN-2 can produce observed cardiac toxicity in vivo at high dose.